Global Health and Trade

Why this matters in health economics

Every framework in this book — opportunity cost, cost-effectiveness thresholds, priority-setting — assumes a bounded budget and a bounded population. Global health breaks that assumption. A pathogen that emerges in one country becomes a fiscal and mortality shock in every country; a patent negotiated in Geneva changes what a health ministry in Nairobi or Manila can afford; a nurse trained at public expense in Malawi may spend her career in Manchester. The unit of analysis is no longer one system but the traffic between systems.

For a director, three practical stakes follow. First, money: a large share of health spending in the poorest countries is external, channelled through bodies such as the Global Fund, Gavi, and the World Bank, and how that money is priced, pooled, and phased out shapes what a national programme can plan. Second, rules: trade agreements, above all the TRIPS Agreement on intellectual property, set the price of the medicines a budget must buy. Third, externalities: pandemics, antimicrobial resistance, and the migration of health workers are cross-border spillovers that no single country's optimization will get right, because the country doing the optimizing does not bear all the costs or reap all the benefits.

The equity stakes are stark. The gap in life expectancy between the richest and poorest countries is measured in decades, and much of it is attributable to conditions that are cheap to prevent. Health economics earns its keep here by making the trade-offs explicit — between funding a vertical disease programme and building a health system, between protecting innovation incentives and widening access, between a rich country's right to recruit and a poor country's right to keep its workforce. None of these have costless answers, and pretending otherwise is the failure this chapter exists to prevent.

Core concepts

Global public goods for health. A global public good is non-rival and non-excludable across national borders: disease surveillance data, the genomic sequence of a new pathogen, the knowledge that a vaccine works. Because no country can be excluded from the benefit and one country's use does not diminish another's, each has an incentive to free-ride and under-invest, so these goods are chronically undersupplied without collective financing. This is the international extension of the public-good and externality problems that Chapter 1.3 — Market Failure develops at the national level; here the missing institution is a world government, so provision depends on treaties, pooled funds, and voluntary cooperation.

Pandemics as global externalities. An outbreak imposes costs — deaths, lockdowns, supply-chain shocks — far beyond the country of origin, so the private national return on preparedness understates the global return. A pandemic is therefore a textbook negative externality with a positive-externality remedy: surveillance, containment, and vaccination in one country protect all others. The International Health Regulations and the mechanism for declaring a public-health emergency of international concern are attempts to internalize this externality through binding notification duties.

The global financing architecture. Development assistance for health flows through several channels: multilateral banks such as the World Bank and its Global Financing Facility; disease-specific vertical funds such as the Global Fund; product-focused bodies such as Gavi, which subsidizes vaccines and shapes markets with tools like an advance market commitment; and bilateral aid. Each has a theory of change — pooling risk, correcting market failure, buying at scale — and each imposes transaction costs, reporting burdens, and the risk of distorting national priorities toward the donor's disease of interest.

Universal health coverage and priority-setting in LMICs. Universal health coverage (UHC) — that all people obtain the services they need without financial hardship — is the organizing goal of global health policy. In low- and middle-income countries (LMICs), the priority-setting problem (Chapter 3.3 — Rationing) is sharper: budgets per person are small, out-of-pocket payment is high, data are thin, and the opportunity cost of a wrong choice is measured in preventable deaths. Outcomes are often expressed in disability-adjusted life years (DALYs) averted, and cost-effectiveness benchmarks are frequently anchored to a country's income per head rather than to a NICE-style fixed threshold.

Trade and health policy space. Trade agreements constrain the levers a health ministry can pull. TRIPS obliges World Trade Organization members to grant pharmaceutical patents, which raises prices above the marginal cost of production; the Doha Declaration of 2001 affirmed that TRIPS should not prevent countries from protecting public health, and preserved flexibilities such as compulsory licensing and parallel importation. Access to medicines in LMICs turns on whether and how these flexibilities are used. Drug pricing mechanics themselves belong to Chapter 2.4 — Pharmacoeconomics; the TRIPS-and-access question is this chapter's.

Medical tourism. Medical tourism — patients travelling across borders for treatment, whether for price, speed, or procedures unavailable at home — is trade in health services. It brings foreign exchange and can cross-subsidize domestic care, but it can also pull scarce clinicians toward a private, export-facing tier and create a two-track system inside one country.

Health-worker migration. The international movement of clinicians, often called the medical "brain drain" or, more neutrally, health-workforce flow, is a transfer of publicly-funded human capital from poorer to richer systems. It is one form of human capital flight. Migration can raise a migrant's welfare and generate remittances, yet leave the source country short of the workers it paid to train.

Best practices

1. Treat cross-border health threats as externalities and price them accordingly. A pandemic, drug resistance, or an unvaccinated population next door imposes costs your own accounts will not show until it is too late. Build the global spillover into the business case for preparedness and for financing others' preparedness — the return on containing an outbreak at source usually dwarfs the return on defending your own border afterward. This is spending you cannot justify on a purely national perspective, which is exactly why it is chronically underfunded.

2. Name the perspective, and say whose money and whose deaths are being counted. As in any economic evaluation (Chapter 2.1 — Economic Evaluation), the conclusion depends on the standpoint — but in global health the standpoints are countries with wildly different budgets. A vaccine that is not cost-effective at a rich-country threshold may avert enormous burden at a poor-country cost. State whether you are optimizing for the donor, the recipient government, the patient, or the world, and do not let a single unstated perspective smuggle in a value judgement.

3. Anchor LMIC priority-setting to local opportunity cost, not an imported threshold. A cost-per-DALY figure borrowed from a high-income agency can badly misrank interventions where the real budget constraint is a fraction of that. Where a country has begun to estimate its own health-system opportunity cost, use it; where it has not, be explicit that income-based rules of thumb are placeholders, and prioritize interventions with strong local evidence of feasibility, not just favourable ratios.

4. Use disease-specific ("vertical") funds without hollowing out the system ("horizontal"). Vertical funds such as the Global Fund and Gavi move money fast against defined killers, but can distort a fragile system toward the funded disease and away from primary care, workforce, and information systems. Negotiate for the health-system-strengthening components these funds increasingly offer, and track whether external money is displacing domestic effort rather than adding to it.

5. Plan for transition and co-financing from day one. External financing is not permanent; as national income rises, countries cross eligibility thresholds and donors withdraw. Model the fiscal cliff early — Gavi and the Global Fund both require rising domestic co-financing and eventual graduation — so that a programme built on external money is not left stranded when it succeeds enough to lose funding.

6. Watch for fungibility and additionality. Earmarked aid can free a recipient government to spend its own money elsewhere, so nominal donor "impact" overstates real impact. Demand honest counterfactual analysis: would the outcome have happened anyway? Design co-financing and results-based mechanisms that make domestic spending additional rather than substituted, and report against that counterfactual, not against gross disbursement.

7. Use TRIPS flexibilities deliberately, and cost the trade retaliation risk. Compulsory licensing, parallel importation, and the "Bolar" research exemption are lawful tools to widen access to patented medicines, affirmed by the Doha Declaration. They are not free: they carry diplomatic and trade-retaliation risks and can chill future investment. Weigh the health gain against those costs openly, and coordinate with other countries and pooled-procurement mechanisms to increase bargaining power and reduce the exposure of acting alone.

8. Separate the innovation question from the access question — then solve both. High patent-protected prices are the mechanism by which research and development is funded (Chapter 5.1 — Innovation Health Economics); simply abolishing them would weaken the incentive to invent. Better to pair strong incentives for innovation with deliberate access instruments — tiered pricing, voluntary licensing to generic manufacturers, patent pools, and advance market commitments — so the reward for inventing does not have to be paid by the poorest patients at the point of need.

9. Govern health-worker migration ethically, and invest in retention. Destination countries should apply ethical-recruitment principles and avoid actively draining source countries that can least afford the loss; source countries should treat retention — pay, conditions, career paths — as an economic investment, not a moral appeal. Remittances and return migration can offset some loss, but they rarely repay the public cost of training a clinician who never practises at home. Bilateral agreements that share training costs and manage flows are more honest than pretending the market will self-correct.

10. Read the trade agreement before you write the health policy. Provisions on intellectual property, services liberalization, investment protection, and tariffs on medical goods can each constrain or enable health policy. Involve health economists in trade negotiations, not only trade officials, so that "policy space" — the room to tax, regulate, or license in the public interest — is defended before it is signed away.

11. Build global public goods through pooled financing, because no one country will fund them alone. Surveillance networks, pathogen genomics, open clinical-trial data, and a functioning outbreak-response capacity are non-excludable and will be under-provided by national budgets. Support the multilateral instruments that pool this financing, and frame domestic contributions to them as insurance premiums against catastrophic tail risks, not as charity.

12. Manage medical tourism so it strengthens rather than cannibalizes the domestic system. Cross-border patient flows can bring revenue and skills, but can also divert clinicians into a private export tier and leave the public system short. Where a country pursues medical tourism as industrial policy, ring-fence public-service obligations, tax the private tier to cross-subsidize public care, and monitor the internal brain drain from public to private that export demand creates.

Questions to discuss with your team

1. When external donors fund a specific disease, how do we protect the priorities our own population would have chosen? Vertical funds arrive with their own targets, timelines, and reporting, and it is rational for a health ministry to follow the money — but the disease a donor cares about is not always the largest local burden, and a programme optimized for the funder can starve primary care and the workforce. The honest tension is between taking money that saves lives now and preserving the autonomy to build a balanced system. Concrete angles: does the grant include health-system-strengthening components, and are we using them? Are we tracking whether external money is additional to domestic effort or merely displacing it? What happens to the disease programme's patients when the grant ends? A good answer names the specific distortions the funding creates, the mitigations negotiated into the grant, and a transition plan — rather than either refusing useful money or accepting it uncritically.

2. If a life-saving medicine is priced out of reach, under what conditions would we use a compulsory licence — and what would it cost us beyond the drug? Compulsory licensing is lawful and Doha-affirmed, and for a genuine public-health need it can cut prices dramatically, but it is a serious act with consequences beyond the medicine cabinet. The tension is between the immediate, measurable health gain and the diffuse, delayed costs: trade friction, reputational risk with investors, and the argument that weakening patents today reduces the medicines invented tomorrow. Concrete angles: is the price gap large enough and the need acute enough to justify it? Have we exhausted voluntary licensing, tiered pricing, and pooled procurement first? Can we act with a coalition of countries rather than alone? An honest answer sets a threshold in advance for when the tool is warranted, quantifies the retaliation and investment-signal risks rather than waving them away, and treats the licence as one instrument in a sequence, not a first resort.

3. We are losing clinicians we trained to richer countries — is that a loss to manage, or a flow to work with? Framing decides policy. Treat migration purely as theft of human capital and you reach for restrictions and resentment; treat it purely as free labour-market choice and you ignore the real public cost of training a workforce that leaves. The tension is that both framings hold some truth: migration raises individual welfare and can send back remittances and skills, yet it can leave a rural district without a single doctor. Concrete angles: what does it actually cost us to train a clinician, and what fraction leave? Are destination countries recruiting ethically, or actively draining us? Would investment in pay, conditions, and career paths retain more people than any restriction could? A good answer moves past the moral framing to the economics — the training cost, the retention elasticity of pay and conditions, and the terms of any bilateral agreement — and decides where scarce money buys the most retained clinician-years.

4. How much should we spend defending against a threat that arrives from beyond our borders, when the return on that spending mostly accrues to others? Pandemic preparedness, drug-resistance containment, and support for a neighbour's surveillance are classic cross-border externalities: the country that pays does not capture all the benefit, so every national budget under-invests and the global public good goes chronically undersupplied. The tension is between a finance ministry's rational reluctance to fund what it cannot fully claim, and the catastrophic tail risk that no border can keep out. Concrete angles: what is the expected cost to us of an outbreak we failed to help contain at source, and how does it compare with the cost of contributing to containment there? Are we treating contributions to pooled surveillance and outbreak-response capacity as charity, or as an insurance premium against a shock that would dwarf them? Would we be better off funding a neighbour's preparedness than hardening our own frontier after the fact? An honest answer prices the spillover explicitly rather than defaulting to a purely national perspective, sizes the tail risk, and decides our contribution to multilateral instruments as risk management, not generosity.

5. If we pursue medical tourism for the foreign exchange it brings, how do we stop it cannibalizing the public system it is meant to help? Cross-border patient flows can earn hard currency, retain skills, and cross-subsidize domestic care, but the same export tier can quietly pull scarce clinicians out of the public wards and lengthen the queues of the citizens who cannot pay. The tension is between medical tourism as industrial policy — jobs, revenue, prestige — and the internal brain drain it sets loose from public to private. Concrete angles: how many specialists would an export facility absorb, and what does that do to public waiting lists? Are we binding public-service obligations and a levy on the private tier into the deal, or hoping the revenue trickles back? Who actually captures the foreign exchange, and does any of it reach the public system? A good answer models the internal workforce shift rather than only the balance-of-payments gain, ring-fences public capacity and cross-subsidy in advance, and treats the two-track risk as the price to be managed, not ignored.

6. When our success lifts us across a donor's income threshold and the external money starts to taper, how do we avoid building a system that collapses the moment it works? Concessional financing is temporary by design: as national income rises, countries cross eligibility lines, co-financing obligations ramp up, and donors eventually graduate them out. The tension is between the pull to expand programmes while the external money is flowing and the fiscal cliff waiting a few years out, when domestic revenue must rise faster than it plausibly can. Concrete angles: have we actually modelled the co-financing ramp and the graduation date, or are we planning as if the money were permanent? What happens to a programme's patients when the grant ends? Are we banking today's savings against that cliff, or spending them on commitments we cannot sustain? An honest answer treats transition arithmetic as a first-order design constraint, models the ramp and the cliff from day one, and prefers durable, domestically-financeable programmes over ones that only balance while the donors are watching.

In practice: a health economics example

The Republic of Serawi is a fictional lower-middle-income country of 40 million people. Its Ministry of Health runs on a small per-person budget; roughly a third of health spending is out-of-pocket and a significant share of programme money is external. Serawi has just crossed the World Bank income threshold at which it begins to "transition" out of the most concessional Gavi and Global Fund support, meaning rising domestic co-financing and, within a decade, graduation. The finance minister wants a plan that does not collapse when the external money tapers.

Three decisions land on the desk of Serawi's newly-formed Health Technology Assessment unit at once. First, a manufacturer has offered a new hepatitis C direct-acting antiviral at a patented price the programme cannot afford at scale; a generic version exists but is blocked by a national patent. Second, a Gulf-based hospital group proposes a public-private "medical city" to attract regional medical tourists, promising foreign exchange and jobs but requesting the secondment of specialists from the public teaching hospital. Third, a donor offers a large, disease-specific grant for a single condition that is not among Serawi's top three causes of DALYs.

The unit refuses to treat these as three separate files. On the antiviral, it estimates the local opportunity cost of the programme budget rather than importing a rich-country threshold, and finds the patented price would displace far more health elsewhere than it buys. It sequences its options: first seek a voluntary licence and tiered price, then join a regional pooled-procurement group to strengthen bargaining power, and only if those fail prepare a compulsory licence under the Doha flexibilities — costing, explicitly, the trade-friction and investment-signal risks and setting them against the DALYs the generic would avert. On the medical city, the unit models the internal brain drain: seconding specialists to an export tier would lengthen public waiting lists, so it recommends approval only with a ring-fenced public-service obligation and a levy on the private tier to cross-subsidize public care. On the donor grant, it applies the fungibility test — would accepting it merely let the government shift its own money away from the funded disease? — and negotiates for health-system-strengthening components and a transition schedule before accepting.

The uncomfortable part is the transition arithmetic. Modelling the co-financing ramp shows a fiscal cliff four years out: as external money withdraws, domestic spending must rise faster than projected revenue. The unit's recommendation is unglamorous — bank the savings from the generic antiviral and the private-tier levy against that cliff, rather than expanding programmes that cannot be sustained once the donors leave. The lesson generalizes: in an LMIC facing transition, the scarcest resource is not any single medicine or specialist but the fiscal room to keep a system running after the world's attention, and its money, moves on.

Four sector lenses

Startup

A small global-health venture — a diagnostics start-up, a telemedicine pilot, a social enterprise selling subsidized medicines — lives or dies on market-shaping instruments it does not control. Its economics turn on whether a pooled procurer or an advance market commitment will guarantee volume, whether a patent pool grants it a licence, and whether donor co-financing survives the recipient's transition. The start-up's edge is speed and focus; its exposure is that a single donor's pivot, or the end of a grant cycle, can erase its market overnight. It should design for the transition cliff from the outset and avoid business models that assume permanent concessional financing.

Small business

A small but established provider or supplier — a private clinic serving cross-border patients, a family-run pharmaceutical distributor, a regional generics wholesaler — competes on steady operations rather than on a single funded pilot. Its exposure to global forces is concrete and recurring: the patented-versus-generic price of the medicines it stocks, the tariff and registration rules that govern what it can import, and the pooled-procurement contracts it may be too small to win alone. Unlike a start-up chasing a market to shape, it already has a book of customers and a cash flow to protect, so its risks are margin compression from price shocks and losing skilled staff to a better-paying export tier or an overseas recruiter. It should join pooled purchasing and professional bodies to gain the bargaining scale it lacks on its own, and watch trade and licensing changes that move its input costs. Its edge is local knowledge and durable relationships that a transient venture cannot match.

Enterprise

A large enterprise — a multinational manufacturer, an international non-governmental organization, or a hospital group running medical-tourism facilities — is a price-setter and a shaper of policy space. Its decisions on tiered pricing, voluntary licensing, and ethical recruitment materially change access and workforce flows across whole regions, and it is the counterparty when a government weighs a compulsory licence. Reputationally and commercially it must reconcile the innovation-reward argument with the access argument, because being seen to price the poorest out of a life-saving product is a strategic risk as well as an ethical one. Enterprises with the scale to segment markets can often widen access and protect revenue at once — if they choose to.

Government

A government carries the accountability the other two do not: it defends policy space in trade talks, decides whether to use TRIPS flexibilities, sets co-financing and transition strategy, and governs migration and medical tourism. It optimizes for its own population, yet its choices generate cross-border externalities — an outbreak unreported, a licence issued, a workforce recruited — that the world feels. National ministries also contribute to the global public goods, from surveillance to pooled funds, that no single country will finance alone. The government's hardest task is temporal: sustaining a system through the fiscal cliff of donor transition while defending, in rooms full of trade officials, the room to act in health's interest at all.

Common failure modes

• Importing a rich-country cost-effectiveness threshold into a poor country. A ratio that looks favourable at a high-income benchmark can be ruinous against a small local budget. Fix: anchor to local opportunity cost, or state clearly that income-based rules of thumb are placeholders.
• Counting donor disbursement as impact. Gross money moved is not health produced, especially when aid is fungible. Fix: report against an honest counterfactual and design for additionality.
• Letting vertical funds hollow out the system. Chasing earmarked disease money can starve primary care, workforce, and data systems. Fix: negotiate health-system-strengthening components and monitor domestic displacement.
• Ignoring the transition cliff. Programmes built on concessional financing collapse when countries graduate. Fix: model co-financing ramps and graduation from day one and bank savings against them.
• Treating a compulsory licence as either taboo or a first resort. Both extremes are wrong — refusing to consider it forfeits leverage, reaching for it first forfeits diplomacy. Fix: set a threshold in advance and sequence voluntary licensing and pooled procurement ahead of it.
• Pursuing medical tourism without ring-fencing public care. An export tier can quietly drain clinicians from the public system it was meant to subsidize. Fix: bind public-service obligations and cross-subsidy into the deal, and monitor the internal brain drain.
• Moralizing health-worker migration instead of costing it. Both "theft" and "free choice" framings dodge the arithmetic. Fix: measure training cost and retention elasticity, and buy retained clinician-years where they are cheapest.

Maturity model

Checklist

• State the perspective — donor, recipient government, patient, or world — before any global-health business case.
• Anchor LMIC priority-setting to local opportunity cost, not an imported threshold; note where a threshold is a placeholder.
• Model the external-money share, the co-financing ramp, and the graduation cliff for every externally-funded programme.
• Apply the fungibility and additionality test to donor funding before claiming impact.
• For an unaffordable patented medicine, sequence voluntary licensing, tiered pricing, and pooled procurement before a compulsory licence — and set a licence threshold in advance.
• Cost the trade-retaliation and investment-signal risks of using TRIPS flexibilities, not just the health gain.
• Measure the public cost of training clinicians and the retention effect of pay and conditions before choosing a migration response.
• Ring-fence public-service obligations and cross-subsidy into any medical-tourism arrangement.
• Treat pandemics and drug resistance as externalities; build the global spillover into preparedness business cases.
• Involve health economists in trade negotiations to defend policy space before it is signed away.

Key sources

• World Health Organization — health financing, universal health coverage, and the WHO Global Code of Practice on the International Recruitment of Health Personnel.
• World Bank — health financing and the Global Financing Facility; income classifications governing donor transition.
• The Global Fund to Fight AIDS, Tuberculosis and Malaria — co-financing and transition policies.
• Gavi, the Vaccine Alliance — advance market commitments and country co-financing and graduation policies.
• World Trade Organization — the TRIPS Agreement and the 2001 Doha Declaration on the TRIPS Agreement and Public Health.
• Smith, Beaglehole, Woodward & Drager (eds.), Global Public Goods for Health (Oxford University Press); Smith, "Global public goods and health" (Bulletin of the World Health Organization, 2003).
• Bettcher, Yach & Guindon, "Global trade and health: key linkages and future challenges" (Bulletin of the World Health Organization, 2000).

References

1. Global health — Wikipedia — https://en.wikipedia.org/wiki/Global_health
2. The Global Fund to Fight AIDS, Tuberculosis and Malaria — Wikipedia — https://en.wikipedia.org/wiki/The_Global_Fund_to_Fight_AIDS,_Tuberculosis_and_Malaria
3. Gavi — Wikipedia — https://en.wikipedia.org/wiki/Gavi
4. World Bank — Wikipedia — https://en.wikipedia.org/wiki/World_Bank
5. TRIPS Agreement — Wikipedia — https://en.wikipedia.org/wiki/TRIPS_Agreement
6. Global public good — Wikipedia — https://en.wikipedia.org/wiki/Global_public_good
7. Universal health coverage — Wikipedia — https://en.wikipedia.org/wiki/Universal_health_coverage
8. Disability-adjusted life year — Wikipedia — https://en.wikipedia.org/wiki/Disability-adjusted_life_year
9. Doha Declaration — Wikipedia — https://en.wikipedia.org/wiki/Doha_Declaration
10. Compulsory license — Wikipedia — https://en.wikipedia.org/wiki/Compulsory_license
11. Medical tourism — Wikipedia — https://en.wikipedia.org/wiki/Medical_tourism
12. Human capital flight — Wikipedia — https://en.wikipedia.org/wiki/Human_capital_flight
13. World Trade Organization — Declaration on the TRIPS Agreement and Public Health (Doha, 2001) — https://www.wto.org/english/thewto_e/minist_e/min01_e/mindecl_trips_e.htm
14. World Health Organization — WHO Global Code of Practice on the International Recruitment of Health Personnel — https://www.who.int/publications/i/item/wha68.32
15. Smith R, Beaglehole R, Woodward D, Drager N (eds.) — Global Public Goods for Health — Oxford University Press — https://global.oup.com/academic/product/global-public-goods-for-health-9780198527985